Maternal CD4+ cell count decline after interruption of antiretroviral prophylaxis for the prevention of mother-to-child transmission of HIV

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Ekouevi, Didier ^a,b   Abrams, Elaine J ^c,d   Schlesinger, Malka ^c   Myer, Landon ^e   Phanuphak, Nittaya ^f   Carter, Rosalind J ^c  

^a PACCI   (Côte d’Ivoire)

^b INSERM   (France)

^c Department of Medicine   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DELIVERY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAPARTUM CARE; MAJOR CLINICAL STUDY; PERINATAL INFECTION; PREGNANCY; SHORT COURSE THERAPY; SINGLE DRUG DOSE; VERTICAL TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOTHERS; MULTIVARIATE ANALYSIS; PREGNANCY; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84865409532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043750     Document Type: Article

References (22)

1. WHO (2006) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach. Available: http://www.who.int/hiv/pub/mtct/pmtct/en/. Accessed 2012 Jul 18.
2. WHO (2010) Recommendations for use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Available: http://www.who.int/hiv/pub/mtct/guidelines/en/. Accessed 2012 Jul 18.
3. The Kesho-bora study group (2012) Maternal HIV-1 Disease Progression 18-24 Months Postdelivery According to Antiretroviral Prophylaxis Regimen (Triple-Antiretroviral Prophylaxis During Pregnancy and Breastfeeding vs Zidovudine/Single-Dose Nevirapine Prophylaxis): The Kesho Bora Randomized Controlled Trial. Clin Infect Dis 55(3): 449-460.
4. Watts DH, Lu M, Thompson B, Tuomala RE, Meyer WA, et al. (2009) Treatment interruption after pregnancy: effects on disease progression and laboratory findings. Infect Dis Obstet Gynecol 2009: 456717.
5. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, et al. (2006) CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 367(9527): 1981-9.
6. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355(22): 2283-96.
7. Rabkin M, El-Sadr W (2004) Saving mother, saving families: the MTCT-Plus initiative (case study). Geneva, Switzerland: WHO.
8. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, et al. (2010) Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLoS Med 7(2): e1000229.
9. Toro PL, Katyal M, Carter RJ, Myer L, El-Sadr WM, et al. (2010) Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. AIDS 24(4): 515-24.
10. Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, et al. (2007) Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 4(8): e257.
11. UNAIDS (2011) Global Plan towards the elimination of new HIV infections along children by 2015 and keeping their mothers alive. 2011-2015. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20110609_JC2137_Global-Plan-Elimination-HIV-Children_en.pdf. Accessed 2012 Jul 18.
12. Palacios R, Senise J, Vaz M, Diaz R, Castelo A, (2009) Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers. HIV Med 10(3): 157-62.
13. Cavallo IK, Kakehasi FM, Andrade BA, Lobato AC, Aguiar RA, et al. (2010) Predictors of postpartum viral load rebound in a cohort of HIV-infected Brazilian women. Int J Gynaecol Obstet 108(2): 111-4.
14. Fowler M, Brown E, Maldonado Y, Chipato T, Manjii K, et al. (2012) Maternal Disease Progression in the First Year after Delivery among HIV+ African Women: HPTN 046 Clinical Trial (abstract#1015). 19th Conference on Retroviruses and Opportunistic Infections; 2012 March-5-8,2012; Seattle, USA.
15. WHO (2012) Programmatic Update. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Executive summary. Available: http://www.who.int/hiv/pub/pmtct_update.pdf. Accessed 2012 Jul 18.
16. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365(6): 493-505.
17. Rosen S, Fox MP, (2011) Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 8(7): e1001056.
18. Arrive E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, et al. (2010) Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance. Aids 24(16): 2481-8.
19. Arrive E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, et al. (2009) Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS 23(7): 825-33.
20. de Jong MD, de Boer RJ, de Wolf F, Foudraine NA, Boucher CA, et al. (1997) Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. Aids 11(11): F79-84.
21. Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, et al. (2007) Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 195(10): 1426-36.
22. Koyanagi A, Ruff AJ, Moulton LH, Ntozini R, Mutasa K, et al. (2008) Postpartum plasma CD4 change in HIV-positive women: implications for timing of HAART initiation. AIDS Res Hum Retroviruses 26(5): 547-52.